SymbioPharm GmbH

SymbioPharm GmbH is a health care startup with the slogan "Our mission: bacteria for therapy." Founded in 1954, the company focuses on utilizing probiotic bacteria to enhance health and well-being through exploring the human microbiome. SymbioPharm is a global leader in microbiome research and evidence-based probiotics. The company's state-of-the-art biotech laboratory and collaboration with in-house physicians and medical scientists enable the creation of innovative products, including Symbioflor® 1, one of the initial probiotic pharmaceuticals globally. Fully integrated from R&D to pharmaceutical production in Germany, SymbioPharm operates at the highest quality standards. The company is part of a privately held group consisting of the Institute of Microecology for microbiome diagnostics, Ambulatory healthcare center (MVZ), and SymbioVaccin for personalized therapies. SymbioPharm's growing product portfolio, available in 16 countries globally, comprises over 20 products of pharmaceuticals, nutritional and dietary supplements, as well as medicinal products. The vision of SymbioPharm is becoming a reality, as approximately 2.5 million drops of their Symbioflor products are used daily across the globe for therapy and prevention. The company caters to thousands of customers who use their pro- and prebiotic products daily to improve and maintain their health. SymbioPharm's mission to utilize the biological effect of naturally occurring bacteria to improve health and well-being is evident in their impact on global health, as they affirm that the "health of tomorrow starts with the probiotics of today."